Published trade mark details for 2477997
This information was published on 2026-01-08T11:22:06 for IP Right Registration Published.
| Field | Value |
| (210) | 2477997 (IR 1807228) |
| (220) |
05 Jul 2024
|
| (300) |
SG, 08 Jan 2024, 40202400528T
|
| (500) |
The applicant has advised that the words in the Mark have no meaning in English
|
| (511) (510) |
Class 5
Nucleic acid sequences and chemical reagents for medical purposes; pharmaceutical preparations for the treatment of genetic diseases and disorders; genetic medicines for the treatment of diseases and disorders with known genetic cause or component and disease states resulting from gene expression or genetic sequence; nucleic acid therapeutic agents for the treatment of Huntington's disease, Duchenne muscular dystrophy, and alpha-1 antitrypsin deficiency; pharmaceutical preparations for the prevention, diagnosis, and treatment of metabolic, cardiometabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, renal, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric, autoimmune and immune system related diseases and disorders. Class 42 Research and development in the fields of pharmaceuticals, genetics, therapeutics, and drug formulation and delivery; scientific research; scientific research in the fields of pharmaceuticals, medicine, and nucleic acid therapeutics; research, development, and testing services in the field of nucleic acid therapeutics for medical and scientific applications; medical research; laboratory research services relating to pharmaceuticals. |
| (540) |
|
| (550) | Figurative |
| (730) |
Wave Life Sciences Ltd.
|
| (750) |
Davies Collison Cave Pty Ltd
|
Find out more about publications on the About page.